VCT220
Phase 2Small molecule
VCT220 is one of 54 small molecule programs targeting Hypertension. It is currently in Phase 2.
3
Indications
5
Total Trials
3
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
VCT220
VVincentage Pharma Co., Ltd
Phase 2
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity2 trials
Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VCT220. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVincentage Pharma Co., Ltd